{"success":true,"data":{"pressRelease":{"id":"17947","rtpr_id":"nGNX2JZBCp","ticker":"AQST","exchange":"NASDAQ","all_tickers":["AQST"],"title":"AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST","author":"Globe Newswire","published_at":"2026-05-02T20:00:00.099Z","article_body":"NEW YORK, May 02, 2026 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of\nsecurities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16,\n2025 and January 8, 2026, both dates inclusive (the “Class Period”), of\nthe important May 4, 2026 lead plaintiff deadline.\n\nSO WHAT: If you purchased Aquestive securities during the Class Period you may\nbe entitled to compensation without payment of any out of pocket fees or costs\nthrough a contingency fee arrangement.\n\nWHAT TO DO NEXT: To join the Aquestive class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=55756 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action. A class action lawsuit has already been filed. If you wish to\nserve as lead plaintiff, you must move the Court no later than May 4, 2026. A\nlead plaintiff is a representative party acting on behalf of other class\nmembers in directing the litigation.\n\nWHY ROSEN LAW: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually handle securities class actions, but are\nmerely middlemen that refer clients or partner with law firms that actually\nlitigate the cases. Be wise in selecting counsel. The Rosen Law Firm\nrepresents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved, at that time, the largest ever securities class action\nsettlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS\nSecurities Class Action Services for number of securities class action\nsettlements in 2017. The firm has been ranked in the top 4 each year since\n2013 and has recovered hundreds of millions of dollars for investors. In 2019\nalone the firm secured over $438 million for investors. In 2020, founding\npartner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar.\nMany of the firm’s attorneys have been recognized by Lawdragon and Super\nLawyers.\n\nDETAILS OF THE CASE: According to the lawsuit, defendants made false and/or\nmisleading statements and/or failed to disclose the true state of\nAquestive’s New Drug Application (“NDA”) for Anaphylm; pertinently,\nAquestive concealed or otherwise minimized the significance of the human\nfactors involved in the use and deployment of its sublingual film, such as\npackaging, use, administration, and labeling. When the true details entered\nthe market, the lawsuit claims that investors suffered damages.\n\nTo join the Aquestive class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=55756 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor’s ability to share in any potential future recovery is\nnot dependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm, on Twitter:\nhttps://twitter.com/rosen_firm or on Facebook:\nhttps://www.facebook.com/rosenlawfirm/.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n-------------------------------\n\nContact Information:\n\n        Laurence Rosen, Esq.\n        Phillip Kim, Esq.\n        The Rosen Law Firm, P.A.\n        275 Madison Avenue, 40th Floor\n        New York, NY 10016\n        Tel: (212) 686-1060\n        Toll Free: (866) 767-3653\n        Fax: (212) 202-3827\n        case@rosenlegal.com\n        www.rosenlegal.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/745335af-3a3a-4fb5-84c0-fdedc9adf092)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2JZBCp","title":"AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST","author":"Globe Newswire","ticker":"AQST","created":"2026-05-02T20:00:00.099Z","tickers":["AQST"],"exchange":"NASDAQ","article_body":"NEW YORK, May 02, 2026 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of\nsecurities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16,\n2025 and January 8, 2026, both dates inclusive (the “Class Period”), of\nthe important May 4, 2026 lead plaintiff deadline.\n\nSO WHAT: If you purchased Aquestive securities during the Class Period you may\nbe entitled to compensation without payment of any out of pocket fees or costs\nthrough a contingency fee arrangement.\n\nWHAT TO DO NEXT: To join the Aquestive class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=55756 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action. A class action lawsuit has already been filed. If you wish to\nserve as lead plaintiff, you must move the Court no later than May 4, 2026. A\nlead plaintiff is a representative party acting on behalf of other class\nmembers in directing the litigation.\n\nWHY ROSEN LAW: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually handle securities class actions, but are\nmerely middlemen that refer clients or partner with law firms that actually\nlitigate the cases. Be wise in selecting counsel. The Rosen Law Firm\nrepresents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved, at that time, the largest ever securities class action\nsettlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS\nSecurities Class Action Services for number of securities class action\nsettlements in 2017. The firm has been ranked in the top 4 each year since\n2013 and has recovered hundreds of millions of dollars for investors. In 2019\nalone the firm secured over $438 million for investors. In 2020, founding\npartner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar.\nMany of the firm’s attorneys have been recognized by Lawdragon and Super\nLawyers.\n\nDETAILS OF THE CASE: According to the lawsuit, defendants made false and/or\nmisleading statements and/or failed to disclose the true state of\nAquestive’s New Drug Application (“NDA”) for Anaphylm; pertinently,\nAquestive concealed or otherwise minimized the significance of the human\nfactors involved in the use and deployment of its sublingual film, such as\npackaging, use, administration, and labeling. When the true details entered\nthe market, the lawsuit claims that investors suffered damages.\n\nTo join the Aquestive class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=55756 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor’s ability to share in any potential future recovery is\nnot dependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm, on Twitter:\nhttps://twitter.com/rosen_firm or on Facebook:\nhttps://www.facebook.com/rosenlawfirm/.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n-------------------------------\n\nContact Information:\n\n        Laurence Rosen, Esq.\n        Phillip Kim, Esq.\n        The Rosen Law Firm, P.A.\n        275 Madison Avenue, 40th Floor\n        New York, NY 10016\n        Tel: (212) 686-1060\n        Toll Free: (866) 767-3653\n        Fax: (212) 202-3827\n        case@rosenlegal.com\n        www.rosenlegal.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/745335af-3a3a-4fb5-84c0-fdedc9adf092)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-02T20:00:00.163634641Z","server_sent_at_ms":1777752000163},"received_at":"2026-05-02T20:00:00.234Z","source_url":"https://www.globenewswire.com/news-release/2026/04/10/3272076/0/en/rosen-national-trial-lawyers-encourages-aquestive-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-aqst.html"},"analysis":{"id":"13091","press_release_id":"17947","analysis_json":{"redFlags":[],"eventType":"legal_litigation","narrative":"Rosen Law Firm issued a shareholder-solicitation notice naming Aquestive Therapeutics (AQST); no new disclosure from the company itself.\n\nThe release is a routine lead-plaintiff-deadline reminder soliciting investors who purchased securities between June 16, 2025, and January 8, 2026, to contact the firm on a contingency basis.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Laurence Rosen","role":"Founding Partner"},{"name":"Phillip Kim","role":"Attorney"}],"products":["Anaphylm"],"companies":[{"name":"Rosen Law Firm, P.A.","relationship":"plaintiff law firm"},{"name":"Aquestive Therapeutics, Inc.","ticker":"AQST","relationship":"defendant"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Rosen Law Firm. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"AQST"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Rosen Law Firm issued a shareholder-solicitation notice naming Aquestive Therapeutics (AQST); no new disclosure from the company itself.\n\nThe release is a routine lead-plaintiff-deadline reminder soliciting investors who purchased securities between June 16, 2025, and January 8, 2026, to contact the firm on a contingency basis.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","key_figures":{},"named_entities":{"people":[{"name":"Laurence Rosen","role":"Founding Partner"},{"name":"Phillip Kim","role":"Attorney"}],"products":["Anaphylm"],"companies":[{"name":"Rosen Law Firm, P.A.","relationship":"plaintiff law firm"},{"name":"Aquestive Therapeutics, Inc.","ticker":"AQST","relationship":"defendant"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-02T20:01:46.567Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":105481,"modelName":"glm-4.7"}}